NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

自動注射器的全球市場

The global auto injector market by product type, therapy type, indication, route of distribution, end user & regions

出版商 SPER Market Research Pvt. Ltd. 商品編碼 1004267
出版日期 內容資訊 英文 216 Pages
商品交期: 最快1-2個工作天內
價格
自動注射器的全球市場 The global auto injector market by product type, therapy type, indication, route of distribution, end user & regions
出版日期: 2021年05月04日內容資訊: 英文 216 Pages
簡介

全球自動注射器市場,預計從2019年到2027年以18.2%的年複合成長率發展,從2019年的401億美元到2027年達1,531億美元。該市場的主要成長要素,是標靶治療的普及,過敏性反應的發生率上升,對藥物的自我給藥偏好高漲,使用方便的好處,法規當局的批准數量增加,自動注射器的非專利版的利用可能性,有利的償付和政府的輔助,技術的進步等。還有生物製藥的專利到期也成為市場成長機會。

本報告提供全球自動注射器市場的相關調查,市場成長及阻礙因素,機會和課題,各治療、類型、給藥途徑、終端用戶、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

第5章 市場概要

  • 簡介
  • 市場動態
    • 成長要素
    • 阻礙因素
    • 機會
    • 課題
  • 自動注射器市場COVID-19的影響

第6章 產業考察

  • 簡介
  • 產業趨勢

第7章 自動注射器市場:各治療(2020-2027)

  • 類風濕性關節炎
  • 糖尿病
  • 多發性硬化症
  • 過敏性反應
  • 其他

第8章 自動注射器市場:各類型(2020-2027)

  • 拋棄式自動注射器
  • 可重覆使用自動注射器

第9章 自動注射器市場:各給藥途徑(2020-2027)

  • 皮下
  • 肌肉內

第10章 自動注射器市場:各終端用戶(2020-2027)

  • 居家照護
  • 醫院及診療所
  • 門診病人

第11章 自動注射器市場:各地區(2020-2027)

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 南美
  • 中東和非洲

第12章 競爭情形

  • 簡介
  • 競爭現況與趨勢
    • 產品銷售
    • 聯盟,合作,契約
    • 收購
    • 擴張
    • 其他開發

第13章 企業簡介

  • Abbvie Inc.
  • Amgen
  • Elli Lilly and Company
  • Mylan
  • Ypsomed
  • Becton, Dickinson, and Company
  • Glaxosmithkline Plc.
  • Johnson & Johnson
  • Teva Pharmaceutical Industries
  • Antares Pharma, Inc.
  • Merck KGAA
  • Meridian Medical Technologies, Inc.
  • Roche
  • Bespak
  • Bayer AG
  • Bristol-Myers Squibb Company
  • SHL Medical
  • Haselmeter
  • Owen Mumford
  • Ravimed

第14章 附錄

  • 1)討論指南
  • 2)可利用的客製化
  • 3)相關報告
目錄

The global autoinjectors market is projected to reach USD 153.1 billion by 2027 from USD 40.1 billion in 2019, at a CAGR of 18.2% from 2019 to 2027. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favourable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.

On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices. Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Moreover, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These factors could have had a negative impact on the autoinjectors market, especially with their use in healthcare institutions in early 2020. However, the pandemic's overall effect on the autoinjectors is considered positive, especially in the forecast period, due to several factors. Firstly, the demand for effective home care and remote monitoring has increased the relevance of autoinjectors for patients to conveniently and easily manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn's disease, a rheumatoid arthritis patient relying on prefilled syringes and autoinjectors to manage their condition at home.

The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anaemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest share of autoinjectors market. The large share of this segment is mainly attributed to its high prevalence. The increasing incidence of RA fuels the demand for autoinjectors for this therapy segment. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US are affected annually by some form of arthritis, RA, gout, lupus, or fibromyalgia.

Based on type, the autoinjectors market is segmented into reusable and disposable autoinjectors. In 2018, the disposable autoinjectors segment accounted for the largest share of the global autoinjectors market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.

Based on route of administration, the autoinjectors market is segmented intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anaemia, and cancer. The subcutaneous segment accounted for the largest share and it is expected to witness fastest growth during the forecast period. The large share of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.

Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. The home care settings segment accounted for the largest share of the autoinjectors market in 2018. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.

Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies.

Table of Contents

1. Introduction

2. Research Methodology

3. Executive Summary

4. Premium Insights

5. Market Overview

  • 1) Introduction
  • 2) Market Dynamics
    • i. Drivers
    • ii. Restraints
    • iii. Opportunities
    • iv. Challenges
  • 3) COVID-19 Impact of the Autoinjectors Market

6. Industry Insights

  • 1) Introduction
  • 2) Industry Trends

7. Autoinjectors Market, By Therapy, 2020-2027 (USD Million)

  • 1) Rheumatoid Arthritis
  • 2) Diabetes
  • 3) Multiple Sclerosis
  • 4) Anaphylaxis
  • 5) Other Therapies

8. Autoinjectors Market, By Type, 2020-2027 (USD Million)

  • 1) Disposable Autoinjectors
  • 2) Reusable Autoinjectors

9. Autoinjectors Market, By Route of Administration, 2020-2027 (USD Million)

  • 1) Subcutaneous
  • 2) Intramuscular

10. Autoinjectors Market, By End User, 2020-2027 (USD Million)

  • 1) Home Care
  • 2) Hospitals & Clinics
  • 3) Ambulatory Care Settings

11. Autoinjectors Market, By Geography, 2020-2027 (USD Million)

  • 1) North America
    • i. US
    • ii. Canada
  • 2) Europe
    • i. Germany
    • ii. UK
    • iii. France
    • iv. Italy
    • v. Spain
    • vi. Rest of Europe
  • 3) Asia-Pacific
    • i. China
    • ii. Japan
    • iii. India
    • iv. Rest of Asia-Pacific
  • 4) Latin America
  • 5) Middle East and Africa

12. Competitive Landscape

  • 1) Introduction
  • 2) Competitive Situation and Trends
    • i. Product Launches
    • ii. Partnerships, Collaborations, and Agreements
    • iii. Acquisitions
    • iv. Expansions
    • v. Other Developments

13. Company Profiles

  • 1) Abbvie Inc.
  • 2) Amgen
  • 3) Elli Lilly and Company
  • 4) Mylan
  • 5) Ypsomed
  • 6) Becton, Dickinson, and Company
  • 7) Glaxosmithkline Plc.
  • 8) Johnson & Johnson
  • 9) Teva Pharmaceutical Industries
  • 10) Antares Pharma, Inc.
  • 11) Merck KGAA
  • 12) Meridian Medical Technologies, Inc.
  • 13) Roche
  • 14) Bespak
  • 15) Bayer AG
  • 16) Bristol-Myers Squibb Company
  • 17) SHL Medical
  • 18) Haselmeter
  • 19) Owen Mumford
  • 20) Ravimed

14. Appendix

  • 1) Discussion Guide
  • 2) Available Customizations
  • 3) Related Reports